Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET

<< Previous

Bullboard Posts

Next >>

Comment by baggerx99on Nov 21, 2022 8:08pm

195 Views

Post# 35117218

RE:RE:RE:RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET

Lots of brain power working all aspects of piecing together a winning novel safe effective drug.Have the IP longevity extended to optimize reward for a partnering deal. Drug formulated for acute pain indication and broadening the application, and suited for a more timely deveopment path. Many years of learning to make it right. IMHO, I truly believe they have it this time, keen opinion to say this is a risk adverse investment.

MrMugsy wrote:

guilelesscat wrote: I mean it gave a lot more color. Now we know the bottleneck is with logistics, which should be cleared up in March.

Yes, 1 billion for USA sales that is correct.

All in all, it was a informative call, and worth the listen.

Who knows, maybe he's right and soon we'll be looking at a 9x or 10x jump.

otherwise...

It fails the placebo trials, and the stock craders. All we can do now is pray, and hope for good trial participants.

I'd assume that's $1B USD for post-op in the USA alone - then you have Europe, Japan and LATAM to deal.
Then we have other acute.
Then working on an IV form for the futrure.
Then you still have additional future chronic sales.
Lots of milestone opportunities.

Any issues - they can pivot - have the cash to enlist specialist ... as they've done so far.

Stock will eventually make it's move but what's more important right now ... 2 fold to 4 fold difference in dosing compared to old formulation. That seems to be the range. Impressive. No crystals ... amophous.

Boom ! Never been at a less risky point ! Like it !